| P50 | author | Jorge Barriuso | Q57940715 |
| | Sun Young Rha | Q63466586 |
| P2093 | author name string | A Garg | |
| | P Tassone | |
| | Y-J Bang | |
| | Y-K Kang | |
| | R Yu | |
| | T Szado | |
| P2860 | cites work | Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 | Q24321567 |
| | Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab | Q27640593 |
| | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 |
| | Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer | Q27851691 |
| | Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 | Q27860674 |
| | Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 |
| | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 |
| | Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial | Q28254919 |
| | Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) | Q28291395 |
| | Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 |
| | Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative me | Q30376023 |
| | Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data | Q31044850 |
| | Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. | Q33827808 |
| | Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. | Q34002037 |
| | Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex | Q34314489 |
| | Gastric adenocarcinoma: review and considerations for future directions | Q34553773 |
| | Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. | Q34554455 |
| | A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours | Q36610615 |
| | Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010 | Q36775107 |
| | Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy | Q37163797 |
| | Survival of korean adult cancer patients by stage at diagnosis, 2006-2010: national cancer registry study | Q37245897 |
| | Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up | Q37489109 |
| | Population Pharmacokinetics of Therapeutic Monoclonal Antibodies | Q37785528 |
| | A comprehensive review of the pharmacokinetics of approved therapeutic monoclonal antibodies in Japan: Are Japanese phase I studies still needed? | Q38163447 |
| | Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study | Q38964573 |
| | Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models | Q39519148 |
| | Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models | Q39771295 |
| | The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. | Q40571024 |
| | Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth | Q44120544 |
| | Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer | Q44819759 |
| | The 5-year relative survival rate of stomach cancer in the USA, Europe and Japan | Q46082661 |
| | Population pharmacokinetics of rilotumumab, a fully human monoclonal antibody against hepatocyte growth factor, in cancer patients | Q46594664 |
| | A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors | Q46616115 |
| | Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. | Q54525297 |
| | Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status | Q57217085 |
| | The Combination of Exposure-Response and Case-Control Analyses in Regulatory Decision Making | Q63255386 |
| | Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer | Q81378656 |
| | Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer | Q81709409 |
| | Comparative study on overexpression of HER2/neu and HER3 in gastric cancer | Q84302634 |
| | Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer | Q85002519 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| | cisplatin | Q412415 |
| | trastuzumab | Q412616 |
| | capecitabine | Q420207 |
| P304 | page(s) | 660-666 | |
| P577 | publication date | 2014-06-24 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer | |
| P478 | volume | 111 | |